Artal Group S.A. Amicus Therapeutics, Inc. Transaction History

Artal Group S.A.

$214 Million
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$11.43 - $14.24 $11.6 Million - $14.4 Million	-1,014,588 Reduced 50.07%	1,011,776 $11.9 Million
Q4 2023 Feb 09, 2024	SELL	$9.97 - $14.52 $20.3 Million - $29.6 Million	-2,036,203 Reduced 50.12%	2,026,364 $28.8 Million
Q3 2023 Nov 13, 2023	SELL	$11.78 - $13.86 $5.89 Million - $6.93 Million	-500,000 Reduced 10.96%	4,062,567 $49.4 Million
Q2 2023 Aug 11, 2023	BUY	$10.72 - $13.3 $11.1 Million - $13.8 Million	1,036,160 Added 29.38%	4,562,567 $57.3 Million
Q1 2023 May 12, 2023	SELL	$10.91 - $13.54 $5.17 Million - $6.41 Million	-473,593 Reduced 11.84%	3,526,407 $39.1 Million
Q1 2022 May 12, 2022	SELL	$7.89 - $12.48 $15.8 Million - $25 Million	-2,000,000 Reduced 33.33%	4,000,000 $37.9 Million
Q4 2021 Feb 11, 2022	SELL	$9.82 - $12.44 $6.84 Million - $8.67 Million	-696,955 Reduced 10.41%	6,000,000 $69.3 Million
Q3 2021 Nov 12, 2021	BUY	$8.74 - $11.84 $25.8 Million - $34.9 Million	2,946,955 Added 78.59%	6,696,955 $64 Million
Q1 2021 May 14, 2021	BUY	$9.2 - $23.86 $11.5 Million - $29.8 Million	1,250,000 Added 50.0%	3,750,000 $37.1 Million
Q4 2020 Feb 11, 2021	SELL	$13.47 - $24.89 $6.74 Million - $12.4 Million	-500,000 Reduced 16.67%	2,500,000 $57.7 Million
Q3 2020 Nov 13, 2020	SELL	$12.89 - $15.89 $6.45 Million - $7.95 Million	-500,000 Reduced 14.29%	3,000,000 $42.4 Million
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $13.3 Million - $23.5 Million	-1,500,000 Reduced 30.0%	3,500,000 $52.8 Million
Q1 2020 May 14, 2020	BUY	$6.63 - $11.16 $13.3 Million - $22.3 Million	2,000,000 Added 66.67%	5,000,000 $46.2 Million
Q4 2019 Feb 13, 2020	BUY	$7.48 - $10.75 $3.74 Million - $5.38 Million	500,000 Added 20.0%	3,000,000 $29.2 Million
Q2 2019 Aug 09, 2019	SELL	$10.96 - $14.4 $1.1 Million - $1.44 Million	-100,000 Reduced 3.85%	2,500,000 $31.2 Million
Q1 2019 May 10, 2019	SELL	$10.04 - $13.92 $4.02 Million - $5.57 Million	-400,000 Reduced 13.33%	2,600,000 $35.4 Million
Q4 2018 Feb 11, 2019	SELL	$8.38 - $13.44 $8.38 Million - $13.4 Million	-1,000,000 Reduced 25.0%	3,000,000 $28.7 Million
Q3 2018 Nov 09, 2018	BUY	$11.6 - $16.54 $12.8 Million - $18.2 Million	1,100,000 Added 37.93%	4,000,000 $48.4 Million
Q2 2018 Aug 10, 2018	BUY	$13.13 - $17.09 $5.25 Million - $6.84 Million	400,000 Added 16.0%	2,900,000 $45.3 Million
Q1 2018 May 10, 2018	BUY	$13.76 - $17.12 $20.6 Million - $25.7 Million	1,500,000 Added 150.0%	2,500,000 $37.6 Million
Q4 2017 Feb 09, 2018	BUY	$12.51 - $16.24 $3.75 Million - $4.87 Million	300,000 Added 42.86%	1,000,000 $14.4 Million
Q3 2017 Nov 08, 2017	BUY	$11.74 - $15.78 $8.22 Million - $11 Million	700,000	700,000 $10.6 Million

Others Institutions Holding FOLD

# of Institutions

311

Shares Held

312M

Call Options Held

516K

Put Options Held

833K

Vanguard Group Inc Valley Forge, PA

28.8M
Shares

$276 Million
0.01% of portfolio
Perceptive Advisors LLC New York, NY

28.1M
Shares

$269 Million
7.83% of portfolio
Black Rock Inc. New York, NY

24.4M
Shares

$233 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

24M
Shares

$230 Million
0.05% of portfolio
Avoro Capital Advisors LLC New York, NY

23.2M
Shares

$222 Million
3.72% of portfolio

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account